Alpatec: Specialist for spinal diseases plans revenue of 1 billion USD by 2027 - Lake Street sees a 50% price opportunity!
Reading Time: 2 minutes
Alphatec (ATEC) addresses a market of over 8 billion USD as a rapidly growing specialist in surgical spinal treatments. The combination of treatment techniques, implants, and AI-supported informatics systems is expected to provide competitive advantages. The Lake Street analysts see a price target of 18 USD (Buy), indicating a 50% upward potential, as the sale of the US spinal implant business by Stryker could lead to significant market disruptions. According to CEO Pat Miles, the best is yet to come for Alphatec. Competitive advantages are...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
